Close

Kaja Abbas

Assistant Professor
of Disease Modelling

Room
119

LSHTM
Keppel Street
London
WC1E 7HT
United Kingdom

Tel.
+44 (0) 20 7927 2742

My research area is vaccine impact modelling with a focus on estimating the health, economic, and equity impact of vaccination programmes to support evidence-based public health decision-making and inform vaccine policy in collaboration with partners and stakeholders at the global, regional, and national levels. I have worked on impact assessment of different vaccines, including human papillomavirus, measles, Haemophilus influenzae type b, rotavirus, pneumococcal, influenza, dengue, Strep A, typhoid, COVID-19, and basic vaccines in the childhood immunisation schedule, in varied settings of low-, middle-, and high-income countries. 

I welcome collaborations related to estimating vaccination impact in different geographic settings, and you are welcome to contact me.

 

 

 

 

Affiliations

Department of Infectious Disease Epidemiology
Faculty of Epidemiology and Population Health

Centres

Centre for the Mathematical Modelling of Infectious Diseases (CMMID)
Vaccine Centre
Global Health Economics Centre

Teaching

  • Epidemiology of Infectious Diseases
  • Modelling and the Dynamics of Infectious Diseases
  • Statistics for Epidemiology

Research

My research area is vaccine impact modelling with a focus on estimating the health, economic, and equity impact of vaccination programmes at the global, regional, and national levels.

Research Area
Economic evaluation
Infectious disease policy
Vaccines
Modelling
Discipline
Health economics
Epidemiology
Disease and Health Conditions
Infectious disease
Region
World

Selected Publications

Dosing interval strategies for two-dose COVID-19 vaccination in 13 middle-income countries of Europe: Health impact modelling and benefit-risk analysis.
Liu Y; Pearson CAB; Sandmann FG; Barnard RC; Kim J-H; CMMID COVID-19 Working Group; Flasche S; Jit M; Abbas K
2022
The Lancet Regional Health - Europe
Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study.
Li X; Mukandavire C; Cucunubá ZM; Echeverria Londono S; Abbas K; Clapham HE; Jit M; Johnson HL; Papadopoulos T; Vynnycky E
2021
The Lancet
Routine childhood immunisation during the COVID-19 pandemic in Africa: a benefit-risk analysis of health benefits versus excess risk of SARS-CoV-2 infection.
Abbas K; Procter SR; van Zandvoort K; Clark A; Funk S; Mengistu T; Hogan D; Dansereau E; Jit M; Flasche S
2020
The Lancet Global Health
Serostatus testing and dengue vaccine cost-benefit thresholds.
Pearson CAB; Abbas KM; Clifford S; Flasche S; Hladish TJ
2019
Journal of The Royal Society Interface
See more Publications